Why DDC Variations are Becoming Harder to Manage
Managing Drug-Device Combination (DDC) variations is increasingly complex due to the tightening intersection of pharmaceutical and medical device regulations. What starts as a standard change can quickly escalate into regulatory delays due to the following factors:
regenold: Your Integrated Development Partner for DDC Lifecycle Changes
regenold helps turn regulatory complexity into a clear and actionable path. We bring drug and device expertise together, review data proactively and build an integrated variation strategy that is aligned with your products, your organisation and your operating model.
Rather than treating each variation as a standalone fire drill, we help you create a consistent regulatory story across the medicinal product dossier, the device evidence package and, where required, the Notified Body pathway.
Services to Keep Your DDCs Variation-Ready
Variation Readiness Assessment
Rapid, low-effort risk scan for your DDC portfolio
We review a selected set of your key DDCs against the 2026 variation expectations and relevant Article 117 considerations. The aim is to identify where fragmented drug and device data may create avoidable variation risk, delay or regulatory challenge.
Typical scope examples
Pre-filled syringes, auto-injectors, pens, inhalers and co-packaged systems such as products supplied with cups, spoons or needles.
Deliverables
- Portfolio risk snapshot using a green / yellow / red logic
- Shortlist of high-risk gaps and likely business impact
- Prioritised recommendations based on risk and effort
Data Bridging Audit
Align Module 3 and device documentation into one integrated regulatory story
We perform a detailed comparison of your medicinal product dossier and device documentation, including Notified Body Opinion-related material where applicable. The focus is to confirm that critical device characteristics, risk controls, usability elements and supporting evidence are consistently and adequately reflected across the documentation package.
Deliverables
- Detailed gap analysis: Module 3 versus technical documentation / NB-related documentation
- Concrete bridging strategy and submission wording concepts
- List of any additional analyses, tests or justifications needed to support the change pathway
NB Opinion & Article 117 Support
Smooth, predictable interaction with Notified Bodies
For integral DDCs requiring a Notified Body Opinion, we support the preparation, submission and defence of the device documentation. This includes planning the evidence package, anticipating expectations, responding to questions and ensuring that the NB pathway fits coherently within the broader medicinal product variation strategy.
Deliverables
- NBOp strategy and documentation plan
- Drafting and review of submission documentation
- Support with NB questions and follow-up actions
Integrated DDC Variation Roadmap
From isolated fixes to a portfolio-level strategy
We work with your teams to design a cross-product roadmap for relevant DDCs, linking regulatory strategy, technical documentation and lifecycle planning. This helps you prioritise effort, reduce duplication and establish a more scalable approach to future variations.
Deliverables
- Portfolio-level DDC variation roadmap
- RACI across RA, CMC, device/QM and operations
- Implementation plan with timelines and quick wins
Proven Across the DDC Lifecycle: Case Examples
Case example 1: 8-Month NB Opinion Win to Ongoing Development Partnership
A legacy combination product with more than 10 years of market history had outdated Module 3 GSPR-related evidence. Relevant device documentation existed, but it was siloed outside the pharmaceutical dossier.
regenold sorted and structured the documentation, created Annex II technical documentation, updated Module 3 content and built a bridging strategy using existing data only. The result was a positive NB Opinion in eight months, without the need for new testing.
When a later product change project began without the right regulatory alignment, regenold re-engaged, realigned the programme and helped break down silos across RA, CMC and device functions. The outcome was an embedded, cross-functional DDC strategy and a more efficient development path.
Case example 2: 10-Product Portfolio Review Revealed Hidden Reuse Opportunities
regenold performed a DDC portfolio assessment covering 10 products. The review identified product misclassifications, including cases where products had been treated differently despite underlying similarities. It also generated concrete action items, such as updates to product information reflecting incorrect device content.
A key strategic outcome was the identification of data-bridging opportunities between products using identical devices that had previously been treated separately. The result was improved portfolio efficiency, better data reuse and a clearer roadmap for future changes.
Case example 3: From Empty Module 3.2.R to MDR Readiness
For a licensed-in co-packaged legacy product, the client discovered that Module 3.2.R was effectively empty, MDR compliance was incomplete and no device certificate was in place.
regenold performed a full compliance review, identified missing evidence, updated Module 3.2.R with certificate-related data and other required device information, and defined concrete actions for qualification of the co-pack system. The product moved from a non-compliance risk to an MDR-ready dossier with a viable path to continued market presence.
Built Around Your Teams and Ways of Working
Our support is designed to fit into existing structures rather than disrupt them. We combine cross-functional regulatory thinking with practical execution support, whether you need a focused review or a broader long-term collaboration.
- Cross-functional workshops with RA, CMC, device and QM
- Lean templates and checklists aligned to your existing QMS
- Flexible engagement model, from targeted support to ongoing partnership
Ready to Keep Your DDCs Variation-Ready?
Start with a short, focused discussion on your current DDC portfolio and where lifecycle variation risks may be hiding. We can help you identify the pressure points early and define a more integrated path forward.
REQUEST A DDC VARIATION READINESS ASSESSMENTFrequently Asked Questions
What is the main challenge with variations for drug-device combination (DDC) products?
The primary challenge is not the variation itself, but the misalignment between drug and device data. Module 3, technical documentation, and Notified Body expectations often evolve separately, creating inconsistencies that trigger additional questions, delays, or rework during variation procedures.
When should variation readiness be assessed?
Variation readiness should be assessed well before any change is planned. Many regulatory risks originate upstream, when documentation is developed in silos. Early alignment reduces pressure, avoids last-minute gaps, and ensures a smoother lifecycle management process.
Which types of products are most affected by DDC variation complexity?
Products most impacted include:
- Pre-filled syringes
- Auto-injectors and pens
- Inhalers
- Co-packaged systems (e.g., with cups, spoons, or needles)
These products sit at the intersection of medicinal and device regulation, making integrated documentation essential.
What is a Variation Readiness Assessment?
A Variation Readiness Assessment is a rapid, structured risk assessment of your DDC portfolio. It identifies:
- Misaligned or fragmented data
- Potential regulatory risks
- Likely impact on timelines and approvals
The outcome is a prioritised action plan to address issues before they affect submissions.
How does a Data Bridging Audit differ from a standard gap analysis?
A Data Bridging Audit goes beyond identifying gaps. It focuses on:
- Aligning Module 3 with device documentation
- Ensuring consistency across all regulatory evidence
- Defining a coherent submission narrative
It provides practical bridging strategies and wording concepts, not just observations.
When is Notified Body involvement required for DDC variations?
For integral DDCs, changes may require a Notified Body Opinion under Article 117. This typically applies when device-related aspects impact safety, performance, or compliance. Proper planning is essential to avoid delays and ensure alignment with the medicinal product variation strategy.
Can existing data be reused for variation submissions?
Yes — in many cases, existing data can be leveraged effectively. However, it must be:
- Properly structured
- Consistently reflected across documentation
- Scientifically justified within a unified strategy
Strategic data bridging can often avoid unnecessary testing and reduce timelines.
What are the risks of managing DDC variations reactively?
Reactive approaches typically lead to:
- Increased workload under time pressure
- Higher likelihood of inconsistencies
- Additional authority or Notified Body questions
- Delays in approvals or market access
A proactive, integrated approach significantly reduces these risks.
How does regenold support cross-functional alignment?
regenold works across Regulatory Affairs, CMC, device/QM, and operations, helping to:
- Define clear roles and responsibilities
- Align documentation and decision-making
- Establish a repeatable lifecycle strategy
This ensures that variation management is structured, predictable, and scalable.
What outcomes can be expected from an integrated DDC variation strategy?
An integrated approach enables:
- Faster and more predictable variation approvals
- Reduced internal effort and duplication
- Improved data consistency across submissions
- Better reuse of existing evidence
- A scalable model for future lifecycle changes
Ultimately, it transforms variation management from a reactive task into a controlled, strategic process.
Still have questions about your DDC portfolio?
Whether you’re planning your first EU submission or preparing to scale your presence, regenold gives you the insight and operational support to succeed.
REQUEST A DDC VARIATION READINESS ASSESSMENTTel. +49 7632 82 26-0 Email: info@regenold.com